Menu
Menu
Finnadvance
Developing in-vitro models, mimicking human biology for accurate, fast and accessible drug development and research purposes.
- Healthtech
- Seed
Location
Finland
Revenue size
0 (pre-revenue)
Year founded
2019
Funding raised
EUR 2 million
Founders
Prateek Singh
Most relevant investors
Athensmed, Voima Ventures, Icebreaker.vc, Business Finland
Team size
17
Problem
Drugs and other types of medical therapy have different effects on conventional 2D cell cultures and on animals vs. human biology. 90% of the drugs validated in either pre-clinical models or on animals, will fail during the transition to actual human clinical trials.
SOLUTION
By providing the highest, standardized throughput organ-on-chip platform that enables safety, efficacy and toxicology testing in human models, Finnadvance’s technology significantly reduces the number of failing drugs at the often costly trial phases.
Finnadvance’s platform connects microtechnology and molecular biology to enable physiological model development, mimicking human biology reliably directly in the laboratory.
KEY CUSTOMERS AND INTERNATIONAL PRESENCE
Finnadvance is currently focusing on preclinical CROs and pharmaceuticals for early stage drug- and therapy screening. However, the groundbreaking technology has also stirred interest in academia, as it provides critical tools and new opportunities for researchers and biotechs in the development of novel therapy forms.
Team
Founder Prateek Singh and a team of 17 engineers and life science researchers are bringing accumulated knowledge from more than 40 peer-reviewed research papers and 20+ patents to Finnadvance’s mission. CSO Sebastien successfully exited from previous Swiss venture Neurix.
Unique selling point
Finnadvance is presenting the only platform capable of mimicking biological barriers at unmatched throughput. Providing the pharmaceutical industry with faster, cheaper and more accurate R&D opportunities, Finnadvance’s technology is helping the world discover new medicine.
Asia Connection
As the Japanese and Korean pharmaceutical and biotechnology companies represent industry-leading progress in neurological- and oncology drug and therapy development, Finnadvance plans to set up a Japanese office and team by the end of 2022. Finnadvance is therefore seeking talent and investment opportunities in Japan.
Pitch
